VistaGen Therapeutics Inc (VTGN)

[gfp927z]

Johnny, Well, whatever works. If you're making money at it consistently, more power to you. Playing the dead cat bounce as a swing trade isn't a bad strategy, but staying long thru binary events will land you in the poor house.

From past experience, it's generally best to avoid the CNS sector. Depression trials are notorious due to the high placebo effect. You can have a good drug but with a 50% placebo effect you'll never be able to demonstrate it. Depression has been a pharma graveyard for decades.

Two weeks of dosing isn't going to be enough time for AV-101 to show what it can do. They'll need to dose 6, 8, 12 weeks. Ultra fast onset is the realm of Ketamine and its close analogs due to the need to hit the opioid receptor in addition to NMDA (see Stanford study). AV-101 may have efficacy but not ultra fast onset. Relying on AMPA to upregulate BDNF/neurotrophins will take many weeks.

Objectively the chances for the Elevate trial are extremely low, but I'll be pulling for VTGN anyway. The neurosteroid program sounds interesting.